An Thanh Phan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
An Thanh Phan has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Vu N. Ngo
Beckman Research Institute, City of Hope
4 shared publications - Alex F. Herrera
City of Hope, Duarte, CA
3 shared publications - Alexey V. Danilov
City of Hope National Medical Center
3 shared publications - Chengwen Li
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
3 shared publications - Dehui Zou
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
3 shared publications - Elias Campo
Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
3 shared publications
Latest Publications
- Open Access
- 17 March 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (6) , 1
Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma
- 17 March 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (6) , 1
Open AccessGenomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma
- Open Access
- 4 April 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (10)
Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma
- 4 April 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (10)
Open AccessGenomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma
- Open Access
- 2 November 2023
- Published by American Society of Hematology in Blood
- Vol. 142 (Supplement) , 720
Mechanistic Elucidation of the Tumor-Promoting Role of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 in B-Cell Receptor Signaling in Mantle Cell Lymphoma
Disclosures. No relevant conflicts of interest to declare.Figure 1
- 2 November 2023
- Published by American Society of Hematology in Blood
- Vol. 142 (Supplement) , 720
Open AccessMechanistic Elucidation of the Tumor-Promoting Role of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 in B-Cell Receptor Signaling in Mantle Cell Lymphoma
Disclosures. No relevant conflicts of interest to declare.Figure 1
- Open Access
- 24 May 2022
- Published by Elsevier in Cell Reports
- Vol. 39 (8) , 110840
HIV-1 exploits the Fanconi anemia pathway for viral DNA integration
- 24 May 2022
- Published by Elsevier in Cell Reports
- Vol. 39 (8) , 110840
Open AccessHIV-1 exploits the Fanconi anemia pathway for viral DNA integration
- Open Access
- 1 February 2022
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 132 (3)
Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma
Mantle cell lymphoma (MCL) is a phenotypically and genetically heterogeneous malignancy in which the genetic alterations determining clinical indications are not fully understood. Here, we performed a comprehensive whole-exome sequencing analysis of 152 primary samples derived from 134 MCL patients, including longitudinal samples from 16 patients and matched RNA-Seq data from 48 samples. We classified MCL into 4 robust clusters (C1–C4). C1 featured mutated immunoglobulin heavy variable (IGHV), CCND1 mutation, amp(11q13), and active B cell receptor (BCR) signaling. C2 was enriched with del(11q)/ATM mutations and upregulation of NF-κB and DNA repair pathways. C3 was characterized by mutations in SP140, NOTCH1, and NSD2, with downregulation of BCR signaling and MYC targets. C4 harbored del(17p)/TP53 mutations, del(13q), and del(9p), and active MYC pathway and hyperproliferation signatures. Patients in these 4 clusters had distinct outcomes (5-year overall survival [OS] rates for C1–C4 were 100%, 56.7%, 48.7%, and 14.2%, respectively). We also inferred the temporal order of genetic events and studied clonal evolution of 16 patients before treatment and at progression/relapse. Eleven of these samples showed drastic clonal evolution that was associated with inferior survival, while the other samples showed modest or no evolution. Our study thus identifies genetic subsets that clinically define this malignancy and delineates clonal evolution patterns and their impact on clinical outcomes.
- 1 February 2022
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 132 (3)
Open AccessGenomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma
Mantle cell lymphoma (MCL) is a phenotypically and genetically heterogeneous malignancy in which the genetic alterations determining clinical indications are not fully understood. Here, we performed a comprehensive whole-exome sequencing analysis of 152 primary samples derived from 134 MCL patients, including longitudinal samples from 16 patients and matched RNA-Seq data from 48 samples. We classified MCL into 4 robust clusters (C1–C4). C1 featured mutated immunoglobulin heavy variable (IGHV), CCND1 mutation, amp(11q13), and active B cell receptor (BCR) signaling. C2 was enriched with del(11q)/ATM mutations and upregulation of NF-κB and DNA repair pathways. C3 was characterized by mutations in SP140, NOTCH1, and NSD2, with downregulation of BCR signaling and MYC targets. C4 harbored del(17p)/TP53 mutations, del(13q), and del(9p), and active MYC pathway and hyperproliferation signatures. Patients in these 4 clusters had distinct outcomes (5-year overall survival [OS] rates for C1–C4 were 100%, 56.7%, 48.7%, and 14.2%, respectively). We also inferred the temporal order of genetic events and studied clonal evolution of 16 patients before treatment and at progression/relapse. Eleven of these samples showed drastic clonal evolution that was associated with inferior survival, while the other samples showed modest or no evolution. Our study thus identifies genetic subsets that clinically define this malignancy and delineates clonal evolution patterns and their impact on clinical outcomes.